{"entity":{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","aka":["TAZMAN"],"tldr":"A phase 2 trial of Durvalumab, Carboplatin, Cisplatin in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study of AZD2811 + Durvalumab in ES-SCLC is a phase 2 interventional study registered as NCT04745689 by AstraZeneca, with 31 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2022-06-18. Interventions recorded: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide. Conditions listed: Small-Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04745689","url":"https://clinicaltrials.gov/study/NCT04745689"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","carboplatin","cisplatin","etoposide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04745689","phase":"2","setting":"A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer","sponsor":"AstraZeneca","started":"2021-02-23","startedType":"actual","yearReported":2025,"enrolled":31,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS) in Maintenance Participants","unit":"months","arms":[{"name":"AZD2811 + Durvalumab","n":9,"value":9.99,"note":"95% CI 4.14 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-03-27), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04745689?tab=results"}]},"route":"/trials/nct04745689/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}